Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Microbix Biosystems Leads These 3 TSX Penny Stocks To Watch

In This Article:

In 2025, the Canadian stock market has experienced volatility and negative returns amid broader economic uncertainties, highlighting the importance of diversification in investment portfolios. Despite these challenges, certain sectors have shown resilience, offering investors opportunities to explore diverse asset classes. Penny stocks, although a somewhat outdated term, continue to represent potential growth avenues for investors willing to look beyond traditional equities; when grounded in solid financials and fundamentals, they can offer significant upside potential.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

NTG Clarity Networks (TSXV:NCI)

CA$1.87

CA$77.14M

★★★★★☆

NamSys (TSXV:CTZ)

CA$1.12

CA$29.55M

★★★★★★

Madoro Metals (TSXV:MDM)

CA$0.045

CA$3.58M

★★★★★★

Orezone Gold (TSX:ORE)

CA$0.99

CA$453.18M

★★★★★☆

Amerigo Resources (TSX:ARG)

CA$1.93

CA$312.9M

★★★★★☆

Alvopetro Energy (TSXV:ALV)

CA$4.84

CA$167.51M

★★★★★★

PetroTal (TSX:TAL)

CA$0.69

CA$623.15M

★★★★★★

McCoy Global (TSX:MCB)

CA$3.18

CA$78.01M

★★★★★★

Findev (TSXV:FDI)

CA$0.485

CA$13.89M

★★★★★★

BluMetric Environmental (TSXV:BLM)

CA$1.06

CA$39.5M

★★★★★★

Click here to see the full list of 935 stocks from our TSX Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Microbix Biosystems

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Microbix Biosystems Inc. is a life science company that develops and commercializes proprietary biological and technological solutions for human health across North America, Europe, and internationally, with a market cap of CA$54.01 million.

Operations: The company's revenue is primarily generated from product sales amounting to CA$23.00 million, with additional income from licensing fees and royalties totaling CA$0.03 million.

Market Cap: CA$54.01M

Microbix Biosystems Inc., with a market cap of CA$54.01 million, is navigating the penny stock landscape by leveraging its life sciences expertise and expanding its product offerings. Recent developments include a Memorandum of Understanding with the Australian Centre for the Prevention of Cervical Cancer to supply quality assessment products, enhancing their global footprint. Despite a decline in quarterly revenue to CA$6.04 million from CA$8.41 million year-over-year, Microbix maintains financial stability with short-term assets exceeding liabilities and cash surpassing total debt. The company is also broadening capabilities in recombinant antigen production, potentially increasing market share in immunoassays.